Influence of antituberculosis drug resistance and Mycobacterium tuberculosis lineage on outcome in HIV-associated tuberculous meningitis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3074-3079

  Tho, Dau Quang ^a   Estee Torok M ^b   Yen, Nguyen Thi Bich ^c   Bang, Nguyen Duc ^c   Lan, Nguyen Thi Ngoc ^c   Kiet, Vo Sy ^a   Chau, Nguyen Van Vinh ^d   Dung, Nguyen Huy ^c   Day, Jeremy ^a   Farrar, Jeremy ^a   Wolbers, Marcel ^a   Caws, Maxine ^a  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Pham Ngoc Thach Hospital   (Viet Nam)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CEREBROSPINAL FLUID; FATALITY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME; TUBERCULOUS MENINGITIS; VACCINATION; VIET NAM;

EID: 84861168762     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00319-12     Document Type: Article

References (27)

1. American Thoracic Society, CDC, Infectious Diseases Society of America. 2003. Treatment of tuberculosis. MMWR Recommend. Rep. 52(RR-11):1-77.
2. Byrd TF, Davis LE. 2007. Multidrug-resistant tuberculous meningitis. Curr. Neurol. Neurosci. Rep. 7:470-475. (Pubitemid 350107658)
3. Caws M, et al. 2008. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog. 4:e1000034.
4. Caws M, et al. 2006. Beijing genotype of Mycobacterium tuberculosis is significantly associated with human immunodeficiency virus infection and multidrug resistance in cases of tuberculous meningitis. J. Clin. Microbiol. 44:3934-3939. (Pubitemid 44737232)
5. Donald PR. 2011. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb.) 90:279-292.
6. Donald PR, Schoeman JF. 2004. Tuberculous meningitis. N. Engl. J. Med. 351:1719-1720. (Pubitemid 39383206)
7. Gagneux S, Small PM. 2007. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect. Dis. 7:328-337. (Pubitemid 46590063)
8. Heemskerk D, et al. 2011. Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial. Trials 12:25.
9. Krishnan N, et al. 2011. Mycobacterium tuberculosis lineage influences innate immune response and virulence and is associated with distinct cell envelope lipid profiles. PLoS One 6:e23870.
10. Lew W, Pai M, Oxlade O, Martin D, Menzies D. 2008. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann. Intern. Med. 149:123-134. (Pubitemid 352008599)
11. Marais S, Pepper DJ, Marais BJ, Torok ME. 2010. HIV-associated tuberculous meningitis: diagnostic and therapeutic challenges. Tuberculosis (Edinb.) 90:367-374.
12. Menzies D, et al. 2009. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med. 6:e1000146.
13. National Institute for Health and Clinical Excellence. 2011. NICE guidelines, tuberculosis: clinical diagnosis and management of tuberculosis and measures for its prevention and control. The National Collaborating Centre for Chronic Conditions, Royal College of Physicians, London, England.
14. Parwati I, van Crevel R, van Soolingen D. 2010. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect. Dis. 10:103-111.
15. Patel VB, et al. 2004. Multidrug-resistant tuberculous meningitis in Kwa-Zulu-Natal, South Africa. Clin. Infect. Dis. 38:851-856. (Pubitemid 38387234)
16. Quy HT, et al. 2006. Drug resistance among smear-positive tuberculosis patients in Ho Chi Minh City, Vietnam. Int. J. Tuberc. Lung Dis. 10:160-166. (Pubitemid 43275539)
17. R Development Core Team. 2010. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
18. Reed MB, et al. 2004. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431:84-87. (Pubitemid 39215112)
19. Thwaites G, et al. 2008. Relationship between Mycobacterium tuberculosis genotype and the clinical phenotype of pulmonary and meningeal tuberculosis. J. Clin. Microbiol. 46:1363-1368. (Pubitemid 351563580)
20. Thwaites GE, et al. 2005. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J. Infect. Dis. 192:79-88. (Pubitemid 40863860)
21. Thwaites GE, et al. 2004. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N. Engl. J. Med. 351:1741-1751.
22. Torok ME, et al. 2008. Clinical and microbiological features of HIV-associated tuberculous meningitis in Vietnamese adults. PLoS One 3:e1772.
23. Torok ME, et al. 2011. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin. Infect. Dis. 52:1374-1383.
24. Van Buuren S, Groothuis-Oudshoorn K. Multivariate imputation by chained equations in R. J. Stat. Softw., in press.
25. Vinnard C, Winston CA, Wileyto EP, Macgregor RR, Bisson GP. 2010. Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study. BMJ 341:c4451.
26. World Health Organization. 2011. Towards universal access to diagnosis and treatment of multidrug resistant and extensively drug resistant tuberculosis by 2015. WHO Progress Report 2011. WHO/HTM/TB/2011.3. World Health Organization, Geneva, Switzerland.
27. World Health Organization. 2009. Treatment of tuberculosis: guidelines, 4th ed. WHO/HTM/TB/2009.420. World Health Organization, Geneva, Switzerland.